BioSpace News Archive

Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Click Therapeutics, Inc. announce the initiation of the Mirai study, a landmark fully remote clinical trial to investigate the effectiveness of digital therapeutics in reducing depressive symptoms in adults diagnosed with major depressive disorder (MDD) who are on antidepressant monotherapy

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its subsidiary, NV Hemispherx Biopharma Europe, has received formal notification from the European Commission (EC) approving the company’s Orphan Medicinal Product Application for Ampligen as a treatment for pancreatic cancer

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has completed the mouse immunogenicity study with transgenic mice that have been genetically engineered with a gene from the human immune system called the DR4 human leukocyte antigen (HLA) allele

Encompass Health Corporation announced that its board of directors has declared a quarterly cash dividend on its common stock of $0.28 per share, payable on April 15, 2021, to holders of record on April 1, 2021.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 2, 2021 at 9:50 a.m. ET.

The Board of EpiEndo Pharmaceuticals is pleased to announce the appointment of Maria Bech, MSc as Chief Executive Officer (CEO) of the Company, effective immediately.

Genomma Lab Internacional, S.A.B. de C.V., one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, informed that it has uploaded to its investors website a corporate video about the progress on the New Industrial Cluster and the start of operations in the Personal Care Plant, and in the new Logistics Central Warehouse.

Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present an overview of the Company and provide a business update at the following virtual investor conferences.

- Cybrexa and NCI to collaborate on clinical development of Cybrexa’s lead candidate, CBX-12, to assess the safety and efficacy in oncology patients with solid tumors -

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, tipifarnib, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma